Indivior Announces Completion of Redomiciliation to the United States

Core Viewpoint - Indivior Pharmaceuticals, Inc. has completed its redomiciliation from the UK to the US, establishing a new parent company in Delaware and renaming the previous entity to Indivior Ltd, which is now a wholly-owned subsidiary [1][2] Group 1: Redomiciliation Details - The redomiciliation was approved by Indivior shareholders during an extraordinary general meeting on December 11, 2025 [1] - Indivior PLC ordinary shares ceased trading on Nasdaq on January 23, 2026, with shareholders receiving one new common share of Indivior Pharmaceuticals, Inc. for each share held [1] Group 2: Benefits of Redomiciliation - The change in domicile is expected to enhance the benefits of its US stock listing, including compliance with SEC reporting requirements and Nasdaq exchange rules [2] - The company anticipates potential inclusion in additional US equity indices, which could strengthen its market presence [7] - Simplification of corporate governance and reduced complexity are also expected outcomes of the redomiciliation [7] Group 3: Strategic Positioning - The redomiciliation aims to further position Indivior as a US-based treatment innovator, facilitating closer collaboration with public health leaders on advancing SUBLOCADE® for opioid use disorder [7] - Indivior is committed to delivering evidence-based treatment for opioid use disorder and advancing the understanding of this condition as a chronic but treatable brain disease [5]